Error loading player: No playable sources found

  To view this video content in its entirety, click on the "Access Content" button and login to your account.

If you do not have an account, register for free.

Please note that the account you create here is different than your Keystone Symposia account at www.keystonesymposia.org used to register for our multi-day conferences and is uniquely for viewing our virtual content.

  To view this video content in its entirety, click on the "Access Content".


Advancing Nose-to-Brain Delivery of Nucleic Acids through Localization

Date
March 25, 2022
Free
Standard Price
This product is also available as part of the following products:

Advancing Nose-to-Brain Delivery of Nucleic Acids through Localization

Samantha M. Sarett1, Zhefeng Li1, Anisha D’Souza3, Hao-Cheng Chueh1, Christopher Wiethoff1, Peng Fang1, Erica Mondo1, Christina Zhang1, Claire Moront1, Ryan C. Hill1, Sarah Dicker1, Benjamin S. Bleier2, Mansoor Amiji3, Michelle Lynn Hall1
Eli Lilly and Company1; Massachusetts Eye and Ear Institute2; Northeastern University3

Nucleic acids like short interfering RNA (siRNA) are an emerging class of drugs with the capability of addressing previously untreatable (central nervous system) CNS diseases at the genetic level. However, broad clinical application of nucleic acid drugs has been hampered by their inherently poor delivery properties. To date, the only clinically validated option for CNS delivery of nucleic acids is a highly invasive direct injection.
Nose-to-brain delivery (N2B) is a minimally invasive approach that circumvents the BBB and could effectively deliver siRNA to the CNS. Deposition at the olfactory epithelium (located in the upper nasal cavity) allows transport of drugs alongside the olfactory and trigeminal nerves to the brain. However, the fundamental biological differences between rodent and human nasal biology have historically hindered development of drugs that leverage the N2B pathway. For example, 95% of the rodent nasal epithelial surface area allows N2B transit compared to 5 – 8 % for humans. Thus, we hypothesized that a key issue for N2B delivery could be inefficient / variable localization and retention at the target area.
In our investigation of the potential for N2B delivery of nucleic acids, we confirmed the validity of the transit pathway for siRNA therapeutics using pipet-based intranasal instillation in rats. However, absent more efficient localization of dose, magnitude of siRNA delivery was low (1x10-3 – 1x10-2 % ID/g in olfactory bulb and trigeminal nerve). Subsequently, we improved the consistency and degree of siRNA distribution to the CNS through localization by two distinct methods. First, we used catheter-based intranasal infusion in rats to localize the dose to the back of the nasal cavity. Second, we evaluated a translatable approach that both localizes and retains the dose at the rodent epithelium via implantation of a minimally invasive nasal depot (MIND). In both cases, distribution to the brain increased by >10-fold in the olfactory bulb and trigeminal nerve, and siRNA was also quantified in deeper brain regions (e.g., frontal cortex, hippocampus, striatum). RNAScope data depicting siRNA distribution to the olfactory bulb and surface layers of the cortex supported siRNA’s transit through the distinct N2B pathway. In pilot studies, N2B-delivered siRNA also achieved knockdown in regions along that pathway (trigeminal nerve (25%), brain stem (50%), and rostral frontal cortex (20%)).
This data highlights the necessity of efficient localization and retention of siRNA at the olfactory epithelium for effective N2B delivery. Our data shows that addressing this challenge (e.g., via the simple, endoscopic application of MIND in human patients) could bridge the translatability gap for the N2B route. This motivates a continued investigation of the minimally invasive N2B route for delivery of nucleic acid therapeutics to the CNS.

Speaker

Speaker Image for Samantha Sarett
Eli Lilly and Company

Related Products

Thumbnail for Monitoring population-level disease prevalence by measuring SARS-CoV2 in wastewater across a large geographical range
Monitoring population-level disease prevalence by measuring SARS-CoV2 in wastewater across a large geographical range
There is a need for wastewater based epidemiological (WBE) methods that integrate multiple,
Thumbnail for Neural mechanisms underlying GIP’s anti-nausea effect
Neural mechanisms underlying GIP’s anti-nausea effect
Neural mechanism underlying the anti-nausea effect of GIP
Thumbnail for Understanding and De-risking Drug-induced Injection Site Reactions (ISRs) with an Immunocompetent Human Skin Model
Understanding and De-risking Drug-induced Injection Site Reactions (ISRs) with an Immunocompetent Human Skin Model
Upon subcutaneous (SQ) injection of therapeutic drugs, a local inflammatory reaction, commonly referred to as an injection site reaction (ISR), may develop at the injection site. ISRs are characterized by one or more of the following, erythema, edema, pruritus, pain, and induration…
Thumbnail for Charting the Future of Immunology and Immunotherapy
Charting the Future of Immunology and Immunotherapy
This ePanel will celebrate the inaugural winners of the Michelson Philanthropies & Science Prize for Immunology, an international prize that focuses on transformative research in human immunology, with trans-disease applications to accelerate vaccine and immunotherapeutic discovery…
Privacy Policy Update: We value your privacy and want you to understand how your information is being used. To make sure you have current and accurate information about this sites privacy practices please visit the privacy center by clicking here.